URGENT: This Altcoin Opportunity Won’t Wait – Act Now

Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.

Roberto Mignone Biography and Net Worth

Director of Teva Pharmaceutical Industries

Mr. Mignone joined the Board of Directors in 2017.

Mr. Mignone is the Founder and Managing Partner of Bridger Management LLC, a multi-billion dollar investment management firm founded in 2000 and specializing in long-term equity strategies. Since inception, Bridger Management has focused on the healthcare sector and has developed considerable research expertise in support of its investments. In addition to

healthcare, Bridger Management invests in global consumer, technology and financial services companies.

Prior to Bridger Management, Mr. Mignone co-founded and served as a partner of Blue Ridge Capital LLC from 1996 to 2000, an investment management firm specialized in health care, technology, media, telecommunications and financial services. Mr. Mignone serves as a co-Vice Chairman and member of the Finance Committee and Nominating Committee of the New York University Langone Medical Center.

He received a Bachelor of Arts degree in Classics from Harvard College and an M.B.A. from Harvard Business School.

Mr. Mignone serves as Chair of our Finance and Investment Committee and Member of our Audit and Corporate Governance and Nominating Committees.

What is Roberto Mignone's net worth?: The estimated net worth of Roberto Mignone is at least $21.67 million as of June 18th, 2024. Mr. Mignone owns 981,000 shares of Teva Pharmaceutical Industries stock worth more than $21,670,290 as of December 21st. This net worth approximation does not reflect any other assets that Mr. Mignone may own. Learn More about Roberto Mignone's net worth.
How do I contact Roberto Mignone?: The corporate mailing address for Mr. Mignone and other Teva Pharmaceutical Industries executives is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. Teva Pharmaceutical Industries can also be reached via phone at (723) 914-8213 and via email at [email protected]. Learn More on Roberto Mignone's contact information.
Has Roberto Mignone been buying or selling shares of Teva Pharmaceutical Industries?: Roberto Mignone has not been actively trading shares of Teva Pharmaceutical Industries during the last ninety days. Most recently, Roberto Mignone sold 519,000 shares of the business's stock in a transaction on Tuesday, June 18th. The shares were sold at an average price of $17.03, for a transaction totalling $8,838,570.00. Following the completion of the sale, the director now directly owns 981,000 shares of the company's stock, valued at $16,706,430. Learn More on Roberto Mignone's trading history.
Who are Teva Pharmaceutical Industries' active insiders?: Teva Pharmaceutical Industries' insider roster includes Vikki Conway (Acting Head of Global Human Resources), Rosemary Crane (Director), Richard Daniell (VP), Sven Dethlefs (EVP), Eric Drape (VP), Christine Fox (EVP, U.S. Commercial), Richard Francis (President, CEO & Director), Hafrun Fridriksdottir (VP), Eric Hughes (insider), Eliyahu Kalif (CFO), Roberto Mignone (Director), Mark Sabag (Insider), Eli Shani (EVP), David Stark (VP), and Amir Weiss (CAO). Learn More on Teva Pharmaceutical Industries' active insiders.
Are insiders buying or selling shares of Teva Pharmaceutical Industries?: During the last twelve months, insiders at the sold shares 11 times. They sold a total of 984,382 shares worth more than $15,236,840.56. The most recent insider tranaction occured on November, 20th when EVP Christine Fox sold 19,388 shares worth more than $327,075.56. Insiders at Teva Pharmaceutical Industries own 0.6% of the company. Learn More about insider trades at Teva Pharmaceutical Industries.
Information on this page was last updated on 11/20/2024.

Roberto Mignone Insider Trading History at Teva Pharmaceutical Industries

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/18/2024	Sell	519,000	$17.03	$8,838,570.00	981,000
5/10/2018	Buy	750,000	$19.24	$14,430,000.00

Roberto Mignone Buying and Selling Activity at Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Company Overview

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

Today's Range

Now: $22.09

$21.11

$22.17

50 Day Range

MA: $17.79

$16.44

$22.09

2 Week Range

Now: $22.09

$10.34

$22.17

Volume

12,760,563 shs

Average Volume

9,444,773 shs

Market Capitalization

$25.03 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.79

URGENT: This Altcoin Opportunity Won’t Wait – Act Now

From Crypto Swap Profits | Ad

>> Register for the Workshop Now